Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exparel for Burn Donor Site Pain
NCT03705637Phase 1Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bupivacaine in postoperative pain, sponsored by Massachusetts General Hospital. Primary endpoint: Morphine Milligram Equivalents at 3 weeks. Started Jun 2019; status: terminated.
02
Drugs
bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT03705637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03705637.